INSERM, U842, Université de Lyon, Lyon 1, UMR-S842, Faculté de Médecine Lyon-Est, Rue Guillaume Paradin, 69372 Lyon Cedex 08, France.
Mol Cell Endocrinol. 2010 Sep 15;326(1-2):30-9. doi: 10.1016/j.mce.2010.02.043. Epub 2010 Mar 6.
Predicting pituitary tumor behavior remains a challenge, since the prognostic value of identified pathological markers has not yet been evaluated. Genome-wide transcriptome analyses allow the identification of molecular markers to highlight global changes in gene expression and enable the discovery of signaling pathways within complex biological networks. While several transcriptome studies comparing normal with tumoral pituitary as a whole or with respect to subtype have given interesting data concerning pituitary pathogenesis, none have considered pituitary tumor prognosis. Only one study to date, focusing on the pathological classification and progression of prolactin tumors, has identified some molecular markers with diagnostic and prognostic value. We reviewed data in the literature on human pituitary tumor transcriptome and conducted a meta-analysis on the expression of genes involved in cell growth, proliferation and the cell cycle. Based on our expertise, we evaluate the interests and the limitations of using this approach with human pituitary tumors.
预测垂体瘤的行为仍然是一个挑战，因为已确定的病理标志物的预后价值尚未得到评估。全基因组转录组分析可以识别分子标志物，突出基因表达的全局变化，并发现复杂生物网络中的信号通路。虽然几项比较正常垂体与肿瘤垂体整体或亚型的转录组研究提供了有关垂体发病机制的有趣数据，但没有一项研究考虑到垂体瘤的预后。迄今为止，只有一项研究专注于催乳素瘤的病理分类和进展，确定了一些具有诊断和预后价值的分子标志物。我们回顾了文献中关于人类垂体肿瘤转录组的数据，并对涉及细胞生长、增殖和细胞周期的基因表达进行了荟萃分析。基于我们的专业知识，我们评估了这种方法在人类垂体肿瘤中的应用的意义和局限性。
